The FDA just approved a new drug funded by the infamous Ice Bucket Challenge

Eight years later, the fundraising campaign bears fruit.
 By 
Elizabeth de Luna
 on 
Three screenshots of celebs doing the challenge, all mid-water dump. From left to right: Bill Gates, Kim Kardashian being splashed by Ellen DeGeneres, and Ryan Seacrest.
The Ice Bucket Challenges of Bill Gates, Kim Kardashian (with an assist from Ellen DeGeneres) and Ryan Seacrest. Credit: Mashable Composite / Bill Gates YouTube channel / The Ellen Show YouTube channel / On Air with Ryan Seacrest YouTube channel

Remember the viral ice bucket challenge? Normal folks and celebs dumped huge buckets of ice-cold water on their heads in 2014, donated money to the ALS Association, and challenged others to join in, too.

Mark Zuckerberg challenged Bill Gates, Gates challenged Ryan Seacrest, and Seacrest chucked a tiny hotel room ice bucket over his head, donated a paltry $100, and called out David Beckham and Selena Gomez. It was quite a time.

Well, all that water throwing was worth it says the ALS Association, who announced that a drug partly funded by proceeds from the Ice Bucket Challenge was approved by the FDA on Sep. 29.


You May Also Like

According to the association, the challenge raised $115 million from more than 17 million videos, $2.2 million of which went towards the development of the newly-approved medication Relyvrio, which slows the progression of ALS. It's proof that "the Ice Bucket Challenge dramatically accelerated the fight against ALS," says the Association's president and CEO Calaneet Balas.

The chill-inducing trend was created by Pat Quinn and Pete Frates, two young men who were living with ALS and passed away in 2020 and 2019 respectively. “We are thinking of Pat Quinn and Pete Frates," said Balas, "who championed the Ice Bucket Challenge and changed the trajectory of ALS forever.”  

In 2019, an independent research organization surveyed ALS researchers about the impact of resources provided by proceeds from the Ice Bucket Challenge. 84 percent of respondents said support from the Association since the Challenge accelerated their work "quite a bit or very much," while 72 percent of respondents said funding improved their ability to receive additional funding.

Amyotrophic lateral sclerosis, also known as ALS or Lou Gehrig's disease, is a neurodegenerative disease that stiffens muscles and can impair brain function until someone is no longer able to move, eat, speak, or breathe. There is no known cure.

Mashable Image
Elizabeth de Luna
Culture Reporter

Elizabeth is a digital culture reporter covering the internet's influence on self-expression, fashion, and fandom. Her work explores how technology shapes our identities, communities, and emotions. Before joining Mashable, Elizabeth spent six years in tech. Her reporting can be found in Rolling Stone, The Guardian, TIME, and Teen Vogue. Follow her on Instagram here.

Mashable Potato

Recommended For You
How to watch the 2026 winter sports ice hockey online for free
Overhead view of ice hockey player ready to score goal while goalkeeper defending goal in front of goal post during match on ice rink.



'The Daily Show' reacts to Trump's ICE shooting response
Ronny Chieng presents "The Daily Show."

Jimmy Kimmel urges right to act after second deadly ICE shooting: 'How does this end?'
Jimmy Kimmel on 'Jimmy Kimmel Live' with quote overlaid: "Alex Pretti was an ICU nurse who treated veterans, which is about as patriotic I think as it gets."

More in Life

Trending on Mashable
NYT Connections hints today: Clues, answers for April 4, 2026
Connections game on a smartphone

Wordle today: Answer, hints for April 4, 2026
Wordle game on a smartphone

NYT Connections hints today: Clues, answers for April 3, 2026
Connections game on a smartphone


Wordle today: Answer, hints for April 3, 2026
Wordle game on a smartphone
The biggest stories of the day delivered to your inbox.
These newsletters may contain advertising, deals, or affiliate links. By clicking Subscribe, you confirm you are 16+ and agree to our Terms of Use and Privacy Policy.
Thanks for signing up. See you at your inbox!